Solving the Tuberculosis Puzzle |
ADDIS ABABA – The bacteria that cause tuberculosis have been known since 1882, and an effective treatment was developed decades ago. And yet TB remains the world’s deadliest infectious disease.
Daniel Torok/White House via Getty Images Politics 4 Trump’s Iran Quagmire Could Sink America Daron Acemoglu It remains to be seen just how much more damage US institutions will suffer because of President Donald Trump's ill-conceived foreign adventure in the Middle East. What is certain is that the threat to US democracy, social stability, and economic resilience is now greater than at any time in living memory. considers what the latest ill-conceived war in the Middle East will mean for US democracy and soft power.
Trump’s Iran Quagmire Could Sink America
It remains to be seen just how much more damage US institutions will suffer because of President Donald Trump's ill-conceived foreign adventure in the Middle East. What is certain is that the threat to US democracy, social stability, and economic resilience is now greater than at any time in living memory.
Getty Images Longer Reads 2 The Real Fallout From Trump’s Tariffs Jun Du explains why America’s self-defeating trade policy has helped who it was supposed to hurt, and vice versa.
The Real Fallout From Trump’s Tariffs
Kena Betancur/VIEW/press Economics 1 Consumers or Workers First? Dani Rodrik explains why – and how – policymakers should seek to reconcile competing perspectives on what an economy is for.
Consumers or Workers First?
The implications of this stubborn public-health puzzle are dire. In 2024, an estimated 10.7 million people fell ill with TB, but only about 8.3 million were diagnosed. Many of those who go undiagnosed eventually die from the disease. Many more unknowingly spread it.
The “diagnostic gap” – the difference between confirmed and estimated TB cases – is the greatest barrier to an effective global response. Some see this as a technical constraint; but it is not. The tools to detect TB rapidly and accurately now exist and, crucially, can be deployed far closer to where people first seek care, allowing for same-day treatment.
Near-point-of-care (NPOC) molecular tests, which the World Health Organization recently recommended for the first time, represent a new and important tool. They are small, portable, and use easy-to-collect tongue swabs, rather than the phlegm samples that many people – particularly children and those with HIV – struggle to produce. And they are more affordable than other types of molecular tests and instruments.
Equally important, NPOC tests produce results in about 30 minutes, unlike traditional lab tests, which require days or weeks to turn around. That means they can be used for same-day diagnosis in primary-care facilities, such as the community health-care centers that are typically closer to where people live. The testing equipment is battery-powered, meaning patchy national grids need not limit access to life-saving care.
With the Global Fund to Fight AIDS, Tuberculosis, and Malaria starting its next funding cycle in early 2026, eligible countries have an opportunity to secure substantial resources for rolling out and scaling up this new technology. Governments that present detailed roadmaps – including a breakdown of costs, strategies for integrating NPOC tests into national TB plans, and measurable coverage targets – are far more likely to unlock support. Those that fail to act will have to wait three years for the next funding cycle. In global health, timing is often as important as evidence.
Secure your copy of PS Quarterly: Winners & Losers – and save $20
In the new issue of our magazine, leading thinkers examine how recent developments, from the AI revolution to intensifying geopolitical volatility, are reshuffling the economic and financial deck and generating new winners and losers across the global economy.
Subscribe to PS Premium now, with a $20 discount, to read the issue, featuring Claudia Goldin, Mark Blyth, Dambisa Moyo and others.
A slow rollout is indefensible, given the high human cost. Every day, TB spreads quietly and persistently. Delayed diagnosis does not just postpone treatment; it also causes suffering for millions of people by increasing transmission, raising mortality, and accelerating drug resistance. Each untreated case represents an individual tragedy that augurs more untreated cases, adding to the public-health burden.
Global health is full of examples of innovations that took decades to reach scale. For example, even though better-performing molecular TB tests were endorsed over a decade ago, microscopy testing, a century-old technique that misses a substantial share of cases, remains widely used.
Harnessing the transformative potential of NPOC testing requires significant political support for a rapid rollout. That appears to exist on paper. At the United Nations High-Level Meeting on the Fight Against Tuberculosis in 2023, governments committed to achieving universal access to rapid molecular TB tests by 2027. But in several regions with a high disease burden, only a minority of countries are on track to meet that target.
NPOC technology could help close the gap between ambition and reality by decentralizing TB testing. Primary health-care facilities and lower-tier testing centers that still rely on microscopy, especially in rural areas, are obvious candidates for upgrading to NPOC tests, as are high-volume treatment units.
Beyond accelerating the initial rollout of these diagnostics, policymakers must provide training for clinicians, ensure their integration into HIV and community-health programs, and strengthen supportive systems such as supply chains and data management. A rapid test is merely the start of a care pathway; without system-wide preparedness, technological gains could be squandered. Past rollouts have faltered not because the science was weak, but because health systems were not ready.
To translate rhetoric into reality, transparency and accountability will be essential. National roadmaps must include measurable milestones, standardized scorecards, and meaningful reporting mechanisms. Civil-society organizations, often the most effective advocates for underserved patients, must be involved in monitoring progress.
Previous global health campaigns have made it clear that technology can save lives only when it is matched by political ambition. This is the other missing piece of the TB puzzle. To eliminate the scourge of TB once and for all, developing-country leaders must be willing to accelerate the uptake of NPOC tests.